Equity Research Database

Institutional Investment Pitches

Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.

Home Letters Funds Account

Meridian Small Cap Growth Fund's investment thesis on Definium Therapeutics, Inc. ($DFTX) — Q2 2026 | Buyside Digest

All Pitches

View Letter Analysis

$DFTXNASDAQDefinium Therapeutics, Inc.

BULL

Meridian Small Cap Growth Fund—DFTX

Fund Letter

Q2 2026

Published July 28, 2026

View Fund Profile

$45.40USD

+19.2% vs last month

$43.52Pitched

+4.3% since pitch

Market Cap$5.9B

P/E (TTM)N/A

52-Wk RangeN/A

Div. YieldN/A

Technical Chart

From the Fund Letter

Definium's stock more than doubled following strong Phase 3 results for its LSD-based major depressive disorder therapy, which exhibited durable treatment effects and high remission rates. This clinical milestone...

— Chad Meade

BSD Research Exclusive

Unlock Full Institutional Investment Theses

Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.

6,000+ Institutional Pitches

Proprietary AI Analysis

100 Letter Unlocks/Cycle

SUBSCRIBE TO BSD RESEARCH ($55/MO)Compare All Plans

Already a Research or Pro subscriber? Sign In

◆ Keep Reading

What other investors think about $DFTX, and what else Meridian Small Cap Growth Fund is buying.

Other pitches on $DFTX

Other investors who've written on Definium Therapeutics, Inc.

No other institutional pitches found for this ticker yet.

View all $DFTX pitches →